Katalpol shows neuroprotective effects across multiple neurological diseases

Katalpol shows neuroprotective effects across multiple neurological diseases

Announcing a new release forActa Materia MedicaMagazine. Neurological diseases are the leading cause of illness and disability due to increased life expectancy and aging of the global population, highlighting the urgent need and major challenge for the discovery of neuroprotectants with better efficacy and minimal side effects.

Catalpol, an iridoid glycoside derived from Rehmanniae -Radix, has therapeutic potential in neurological diseases due to its diverse biological activities. This review summarizes the research advances and therapeutic potential of katalpol for a wide range of neurological disorders, including depression, cognitive impairment, stroke, Parkinson's disease and multiple sclerosis.

A comprehensive discussion of the experimental models used, dosages, duration of treatment, and mechanisms involved is provided. The common mechanisms underlying the neuroprotective effects of katalpol on these neurological disorders are closely related to antioxidant, anti-neuroinflammatory and anti-apoptotic properties, as well as the ability to promote neuroplasticity and neurogenesis.

Despite the promising results of experimental studies, there are still challenges, such as: B. the identification of direct binding targets, the assessment of toxicological effects and the understanding of pharmacokinetics. Furthermore, well-designed and controlled clinical trials should be conducted to validate the efficacy and safety for the treatment of various neurological diseases. This review provides compelling evidence for katalpol as a promising natural neuroprotective agent.

Sources: